Strategy Announces Approval of STRC Semi-Monthly Dividends
TYSONS CORNER, Va.–(BUSINESS WIRE)–Strategy Inc (Nasdaq: STRF/STRC/STRK/STRD/MSTR; LuxSE: STRE) (“Strategy”) today announced that, based on preliminary... Read more.
Strategy Announces Approval of STRC Semi-Monthly Dividends
TYSONS CORNER, Va.–(BUSINESS WIRE)–Strategy Inc (Nasdaq: STRF/STRC/STRK/STRD/MSTR; LuxSE: STRE) (“Strategy”) today announced that, based on preliminary... Read more.
Strategy Announces Approval of STRC Semi-Monthly Dividends
TYSONS CORNER, Va.–(BUSINESS WIRE)–Strategy Inc (Nasdaq: STRF/STRC/STRK/STRD/MSTR; LuxSE: STRE) (“Strategy”) today announced that, based on preliminary... Read more.
IQM and Real Asset Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination
RAAQ Extraordinary General Meeting Scheduled for June 25, 2026 PRINCETON, N.J. & ESPOO, Finland–(BUSINESS WIRE)–IQM Finland Oy, a global leader in... Read more.
IQM and Real Asset Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination
RAAQ Extraordinary General Meeting Scheduled for June 25, 2026 PRINCETON, N.J. & ESPOO, Finland–(BUSINESS WIRE)–IQM Finland Oy, a global leader in... Read more.
The Massachusetts Innovation Network Announces The 2026 Eddies Finalists
BURLINGTON, Mass.–(BUSINESS WIRE)–#innovation–Now celebrating its 40th anniversary, The Eddies is the oldest and longest-running innovation-boosting... Read more.
Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection
Registry expected to pair Ignite’s reimbursed RPPA platform with structured outcomes tracking across ADC and immunotherapy regimens; initiative expected to generate... Read more.
BostonGene to Present High-Impact AI Models and Biomarker-Driven Frameworks at EHA2026 Congress
Research highlights collaborative studies using predictive multiomics modeling to optimize risk stratification and predict treatment response in blood cancers WALTHAM,... Read more.
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-1
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity... Read more.
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-1
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity... Read more.